Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420527 | 1.00 | SCN9A (0.37) | SCN9AHCRTR2GCGRCACNA1HUSP30 | |
| SCHEMBL15420131 | 0.92 | IDH1 (0.38) | SCN9AHCRTR2GCGRCACNA1HUSP30 | |
| SCHEMBL15420134 | 0.92 | IDH1 (0.38) | SCN9AHCRTR2GCGRCACNA1HUSP30 | |
| SCHEMBL15420589 | 0.92 | IDH1 (0.38) | SCN9AHCRTR2GCGRCACNA1HUSP30 | |
| SCHEMBL12989396 | 0.90 | SCN9A (0.36) | SCN9AHCRTR2GCGRCACNA1HUSP30 | |
| SCHEMBL12989397 | 0.90 | SCN9A (0.36) | SCN9AHCRTR2GCGRCACNA1HUSP30 | |
| SCHEMBL15420691 | 0.89 | HCRTR2 (0.34) | HCRTR2 | |
| SCHEMBL15420677 | 0.89 | HCRTR2 (0.34) | HCRTR2 | |
| SCHEMBL15420248 | 0.88 | SCN9A (0.34) | SCN9AHCRTR2USP30IDH1GPR119 | |
| SCHEMBL15420249 | 0.88 | SCN9A (0.34) | SCN9AHCRTR2USP30IDH1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | SCN9A 648/4885HCRTR2 383/4885GCGR 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.